

**THE FIFTH INTERNATIONAL AIDS MALIGNANCY CONFERENCE  
NATCHER CONFERENCE CENTER, NATIONAL INSTITUTES OF HEALTH CAMPUS  
BETHESDA, MARYLAND  
April 23-25, 2001**

**PROGRAM**

**MONDAY, APRIL 23**

- 8:00 AM – 6:00 PM **POSTER PRESENTATIONS**  
Atrium on First Floor Concourse (Abstracts 26-78)  
Conference Room E on Lower Level (Abstracts 79-95)
- 8:30 AM **Opening Remarks**  
Ellen Feigal, M.D., National Cancer Institute
- 8:45 AM S1 **PLENARY LECTURE**  
**Towards an HIV Vaccine – Immunological Aspects of Resistance to HIV Infection**  
Sara Rowland-Jones, M.A., D.M., F.R.C.P, F.Med.Sci., John Radcliffe Hospital, United Kingdom
- 9:10 AM –11:10 AM **ABSTRACT PRESENTATIONS**  
Moderators: Valerie Beral, M.B.B.S., University of Oxford  
Robert Biggar, M.D., National Cancer Institute
- 9:10 AM 1 **Association of HIV-1 and HIV-2 Infection With Development of High Grade Cervical Neoplasia Among High Risk Women in Senegal**  
Stephen E. Hawes, M.S., University of Washington
- 9:25 AM 2 **Human Herpesvirus 8 (HHV-8) in a Large Cohort of Drug Users at Low Risk for Kaposi's Sarcoma (KS)**  
Nicole Dukers, M.Sc., Municipal Health Services, The Netherlands
- 9:40 AM 3 **Response to Therapy and Prognosis of Childhood KS: Single Center Experience**  
Cecily Banura, M.B.Ch.B., M.S., Uganda Cancer Institute
- 9:55 AM 4 **Malignancies in HIV-positive Patients in Thai National Cancer Institute in Bangkok**  
Arkorn Cheirsilpa, M.D., Thai National Cancer Institute
- 10:10 AM 5 **Novel and Chimeric KSHV Genotypes From South Africa**  
Gary Hayward, Ph.D., Johns Hopkins University
- 10:25 AM 6 **HAART and Its Influence on HPV Related Cervical Disease in Women with HIV**  
Niharika Khanna, M.D., University of Maryland
- 10:40 AM 7 **Highly Active Antiretroviral Therapy Does Not Influence the Natural History of HPV-Related Cervical Lesions**  
Flavia Lillo, M.D., S. Raffale Hospital, Italy

- 10:55 AM 8 **Results From a Phase I Trial of a Microsphere Encapsulated DNA Vaccine For High-grade Anal Dysplasia**  
Barbara Klencke, M.D., University of California, San Francisco
- 11:10 AM Lunch (on your own)
- 12:30 PM **PLENARY LECTURE**  
Moderator: Joel Palefsky, M.D., F.R.C.P., University of California, San Francisco
- S2 **Human Papillomavirus (HPV) Immunology – A Tale of Ignorance, Evasion, and Double Cross**  
Ian Frazer, M.B. Ch.B.(Ed), M.D.(Melb), F.R.C.P.(Ed), F.R.C.P.A., University of Queensland, Australia
- 12:55 PM **ROUNDTABLE - HPV Vaccine**  
Chair: Joel Palefsky, M.D., F.R.C.P., University of California, San Francisco
- S3 **A Dose-ranging Study of the Safety and Immunogenicity of an HPV 11 Candidate Vaccine in Young Healthy Women**  
Kenneth Fife, M.D., Ph.D., Indiana University Medical Center
- S4 **HPV 16 Vaccine Trials**  
Doug Lowy, M.D., National Cancer Institute
- S5 **Plans for a Phase III Efficacy Trial to Evaluate HPV VLP-Based Vaccines**  
Allan Hildesheim, Ph.D., National Cancer Institute
- S6 **Immunization of HPV Positive Patients With High-grade Cervical Dysplasia Using a Microsphere Encapsulated DNA Vaccine (ZYC101): Results in HPV Specific Immune Responses**  
Robert Urban, Ph.D., ZYCOS Inc.
- S7 **Preliminary Data From an Open Label Study of HIV Negative Patients With HSP E7 For Treatment of Anal High-grade Squamous Intraepithelial Lesions**  
Joel Palefsky, M.D., F.R.C.P., University of California, San Francisco
- S8 **Vaccination of Advanced Cervical Cancer Patients With HPV Type 16 E6 or E7 Peptides**  
Samir Khleif, M.D., National Cancer Institute
- 2:25 PM Break
- 2:40 PM - 4:05 PM **PLENARY LECTURES - Genomics, Proteomics, and Bioinformatics**  
Moderators: Richard Ambinder, M.D., Johns Hopkins School of Medicine  
Elliott Kieff, M.D., Harvard University
- 2:40 PM S9 **Gene Expression Profiling of Lymphoid Malignancies Reveals New Cancer Types and Mechanisms of Malignant Transformation**  
Lou Staudt, M.D, Ph.D., National Cancer Institute
- 3:15 PM S10 **Tools for Statistical Exploration of Gene Expression Microarray Data**  
Peter Munson, National Institutes of Health

3:40 PM S11 **Database Issues**  
John Powell, M.S., National Institutes of Health

4:05 PM - 4:35 PM **Authors at Posters**

4:05 PM - 6:00 PM **RECEPTION**  
Atrium on First Floor Concourse  
Conference Room E on Lower Level

## **TUESDAY, APRIL 24**

8:00 AM – 6:00 PM **POSTER PRESENTATIONS**  
Atrium on First Floor Concourse (Abstracts 26-78)  
Conference Room E on Lower Level (Abstracts 79-95)

8:30 AM -10:45 AM **PLENARY LECTURES - Virus Transformation, Oncogenesis, and Cell Genetic Changes**  
Moderator: Elliott Kieff, M.D., Harvard University  
Joseph Pagano, M.D., University of North Carolina

8:30 AM **Molecular Pathogenesis of HIV-associated B Cell Lymphoma**  
Riccardo Dalla Favera, M.D., Columbia University

9:00 AM S12 **HPV Oncogenes Subvert Centrosome Homeostasis: Implications For Cervical Carcinogenesis**  
Karl Munger, M.D., Harvard Medical School

9:30 AM S13 **Manipulation of Notch Signaling by EBV**  
S. Diane Hayward, Ph.D., Johns Hopkins University

10:00 AM Break

10:15 AM S14 **Mechanisms of KSHV Neoplasia**  
Chris Boshoff, M.R.C.P., Ph.D., University College London, United Kingdom

10:45 AM – 12:15 PM **ABSTRACT PRESENTATIONS**

10:45 AM 9 **Detection of High Risk Cervical Intraepithelial Neoplasia and Cervical Cancer by Amplification of Transcripts Derived From Integrated Papillomavirus Oncogenesis**  
Magnus von Knebel Doeberitz, M.D., University of Heidelberg

11:00 AM 10 **Cellular and Intracellular Expression of a Second Viral bcl-2 Homolog Encoded by the BALF1 Reading Frame of EBV**  
William Marshall, M.D., University of Massachusetts Medical School

11:15 AM 11 **NF-KB Activity is Required for the Survival of EBV-transformed Lymphocytes**  
Ellen Cahir-McFarland, Ph.D., Brigham and Women's Hospital

11:30 AM 12 **EBV Nuclear Antigen I Does Not Induce Lymphoma in Transgenic Mice**  
Myung-Soo Kang, Ph.D., Harvard Medical School

11:45 AM 13 **HHV-8 K1 Gene Activates Cells and is Associated With Angiogenesis in Human Tissue Grafts**  
Felipe Samaniego, M.D., M.D. Anderson Cancer Center

- NOON 14 **Genomic Imbalances in AIDS-related Lymphomas Differ From Those Observed in Lymphomas of the Same Category Occurring in Immunocompetent Patients**  
Helen Poirel, M.D., Ph.D., Avicenne Hospital, France
- 12:15 PM Lunch (on your own)
- 1:15 PM - 3:30 PM **PLENARY LECTURES - Virus Replication, Vaccines, and Immunology**  
Moderators: Kenneth Cremer, Ph.D., National Cancer Institute  
Paul Lambert, M.D., University of Wisconsin – Madison
- 1:15 PM S15 **Anti-viral Immune Responses Are Determined by Antigen-dose and -localization Over Time**  
Adrian Ochsenbein, M.D., University of Zurich, Switzerland
- 1:45 PM S16 **Viral and Host Determinants in the Control of Oncogenic Papillomaviruses**  
G rard Orth, D.V.M., Pasteur Institute, France
- 2:15 PM S17 **Prospects for the Immunotherapy of EBV+ Hodgkin’s Disease Using EBV-specific CTLs**  
Cliona Rooney, Ph.D., Baylor College of Medicine
- 2:45 PM Break
- 3:00 PM S18 **CD8+ T Cell Immunity to KSHV**  
Charles Rinaldo, Ph.D., University of Pittsburgh
- 3:30 PM – 5:00 PM **ABSTRACT PRESENTATIONS**
- 3:30 PM 15 **High Prevalence of Novel HPV Genotypes in Women With HIV-Associated Immunodeficiency: Is HPV Commensal Microflora of Genital Mucosa?**  
Thomas Broker, Ph.D., University of Alabama at Birmingham
- 3:45 PM 16 **Interaction of HPV 6/11 E7 Protein With TAP-1**  
Andrea Vambutas, M.D., Long Island Jewish Medical Center
- 4:00 PM 17 **CD4+ Cell Effectors Inhibit EBV-induced B Cell Proliferation**  
Sarah Nikiforow, B.S.E., Yale Medical School
- 4:15 PM 18 **Evidence for Spread of HHV-8 From Tonsillar Germinal Centers to the Epithelial Capsule and Subsequent Release Into Saliva**  
Scott Brodie, D.V.M., Ph.D., University of Washington
- 4:30 PM 19 **Mesenchymal Stem Cells and CD34 Hematopoietic Stem Cells Are Susceptible to KSHV Infection In Vitro**  
Joseph Houry, M.D., Case Western Reserve University
- 4:45 PM 20 **KSHV Immediate-Early Protein ORF45 Blocks Virus-Mediated Induction of Type 1 Interferon by Inhibiting IRE-7 Nuclear Translocation**  
Yan Yuan, Ph.D., University of Pennsylvania
- 5:00 PM - 5:30 PM **Authors at posters**

5:00 PM - 6:00 PM **RECEPTION**  
Atrium on First Floor Concourse  
Conference Room E on Lower Level

**WEDNESDAY, APRIL 25**

8:30 AM - 11:15 AM **PLENARY LECTURES - Mechanisms of Virus Latency, Persistence, Immune Evasion, and Cell Survival**

Moderators: Peter Howley, M.D., Harvard Medical School  
Patrick Moore, M.D., Columbia University

8:30 AM **Immune Evasion**  
Hidde Ploegh, Ph.D., Harvard Medical School

9:00 AM S19 **Molecular Aspects of Latency, Quiescence, and Reactivation of HSV-1**  
Roger Everett, Ph.D., Medical Research Council Virology Unit

9:30 AM S20 **Regulation of the Papillomavirus Lifecycle by the E2 Regulatory Proteins**  
Alison McBride, Ph.D., National Institute of Allergy and Infectious Diseases

10:00 AM Break

10:15 AM S21 **The Segregation Mechanism of Latent EBV Genomes**  
Lori Frappier, Ph.D., University of Toronto

10:45 AM S22 **KSHV: Latency and Immune Evasion**  
Thomas Schulz, M.D., Hannover Medical School, Germany

11:15 AM S23 **PLENARY LECTURE  
The Global HIV/AIDS Pandemic**  
Thomas Quinn, M.D., Johns Hopkins Medical Institution and National Institute of Allergy and Infectious Diseases

11:40 AM Lunch (on your own)

12:40 PM **PLENARY LECTURE**  
Moderator: Thomas Schulz, M.D., Hannover Medical School, Germany.

S24 **The Interplay Between a Gammaherpesvirus and Its Host: Lessons From Murine Gammaherpesvirus**  
Anthony Nash, Ph.D., The University of Edinburgh, Scotland

1:05 PM **ROUNDTABLE - Preclinical Animal Models**  
Chairs: Thomas Schulz, M.D., Hannover Medical School, Germany  
Fred Wang, M.D., Harvard Medical School

S25 **Pathobiology of Simian AIDS-Associated Lymphoma: the Tulane Regional Primate Research Center Experience**  
Laura Levy, Ph.D., Tulane Medical School

S26 **EBV Related Viruses in Old and New World Primates**  
Fred Wang, M.D., Harvard Medical School

S27 **LMP2A Transgenic Mice as a Model for EBV Latent Infection**  
Richard Longnecker, Ph.D., Northwestern Medical School

- S28 **Rhesus Rhadinovirus-Associated Disease in Immunodeficient Rhesus Macaques**  
Scott Wong, Ph.D., Oregon Health Sciences University
- S29 **KSHV Infection in Scid/Human Mouse Models**  
Dirk Dittmer, Ph.D., University of Oklahoma
- S30 **KSHV and KS: Lessons From Transgenic Mice**  
Sergio Lira, M.D., Ph.D., Schering-Plough Research Institute
- S31 **Estrogen-induced Cervical and Vaginal Carcinogenesis in K14-HPV16 Transgenic Mouse-Vaginal/Mucosal Disease**  
Jeffrey Arbeit, M.D., University of California, San Francisco
- S32 **Roles of HPV Type 16 E6 and E7 Genes in Cancer: Insights From the Evaluation of K14E6 and K14E7 Transgenic Mice**  
Paul Lambert, M.D., University of Wisconsin-Madison
- 2:35 PM Break
- 2:50 PM - 4:15 PM **ABSTRACT PRESENTATIONS**  
Moderators: Alexandra Levine, M.D., University of Southern California  
Susan Krown, M.D., Memorial Sloan-Kettering Cancer Center
- 2:50 PM 21 **Detectable Serum IL-10 is More Frequent in Men Who Go On To Develop AIDS-associated B Cell Lymphoma**  
Dr. Elizabeth Crabb Breen, University of California, Los Angeles Medical School
- 3:05 PM 22 **Pilot Trial of Infusional Cyclophosphamide, Doxorubicin, and Etoposide Plus the Anti-CD20 Monoclonal Antibody in HIV-associated Non-Hodgkin's Lymphoma. Preliminary Results of an International Multicentre Trial**  
Umberto Tirelli, M.D., Aviano Cancer Center, Italy
- 3:20 PM 23 **High Dose Chemotherapy and Autologous Stem-cell Transplantation for HIV Associated Lymphoma**  
Jean Gabarre, M.D., Hopital Pitié-Salpêtrière
- 3:35 PM 24 **Feasibility of the Integration of Stanford V CT Regimen With Highly Active Antiretroviral Therapy and G-CSF in Patients With HD and HIV Infection**  
Michele Spina, M.D., Centro di Riferimento Oncologico, Italy
- 3:50 PM 25 **Angiogenesis Inhibitor Col-3 in the Treatment of AIDS-related KS: Final Clinical Analysis and Report of Effects on Matrix Metalloproteinase and Growth Factor Levels**  
Bruce Dezube, M.D., Beth Israel Deaconess Medical Center
- 4:15 PM – 5:30 PM **ROUNDTABLE - Clinical Issues and New Directions in the Treatment of AIDS Malignancies**  
Chair: David Scadden, M.D., Harvard Medical School
- S33 **Developmental Therapy for KS: Major Issues**  
Susan Krown, M.D., Memorial Sloan-Kettering Cancer Center
- S34 **Progress in the Management of HIV-associated NHL in the Age of Highly Active Antiretroviral Therapy**  
Lawrence Kaplan, M.D., University of California, San Francisco

- S35 **Clinical Research in AIDS-Related Malignancies in the HIV and AIDS Malignancy Branch and Collaborators in the National Cancer Institute Intramural Program**  
Robert Yarchoan, M.D., National Cancer Institute
- S36 **Recent Advances and Future Plans on HIV-related Malignant Lymphoma From the Italian Cooperative Group on AIDS and Tumors Experience**  
Umberto Tirelli, M.D., Aviano Cancer Center, Italy
- S37 **The Scientific Agenda for Anogenital HPV-related Lesions**  
Joel Palefsky, M.D., F.R.C.P., University of California, San Francisco
- S38 **New Assays for Herpesvirus Associated Malignancies in AIDS Patients**  
Richard Ambinder, M.D., Ph.D., Johns Hopkins School of Medicine